검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 5-FU |
Overview Company | BeOne Medicines |
Overview Modality | ADC |
Overview Target | Metastatic Colorectal Cancer (CRC) |
Overview Indication | Metastatic Colorectal Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target tumor sites, thereby significantly suppressing CRC growth through the induction of ferroptosis via regulating the FGFR3/PI3K/AKt signaling pathway |
MoA Biomarker | biomarkers offer a promising, non-invasive approach to personalizing treatment strategies potentially enhanci |
PK/PD Species | Rabbit, ration, inhibited xenograft |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit, ration, inhibited xenograft |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Bakuchiol Enhances 5-Fluorouracil Efficacy in Colorectal Cancer Cells via a ROS-Dependent Mechanism Involving Mitochondrial Dysfunction and Apoptosis.. Resistance to 5-fluorouracil (5-FU) remains a major limitation in colorectal cancer therapy, prompting the development of combination strategies aimed at improving its efficacy. Bakuchiol (BAK), a natural compound with reported antioxidant and pro-… |
Clinical Primary efficacy | ORR 72.6% |
Clinical ORR | 72.6% |
Clinical Result source | ClinicalTrials.gov NCT03615326 |
Clinical Data Tier / Score | A · 67 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 5-FU |
Overview Company | BeOne Medicines |
Overview Modality | ADC |
Overview Target | Metastatic Colorectal Cancer (CRC) |
Overview Indication | Metastatic Colorectal Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target tumor sites, thereby significantly suppressing CRC growth through the induction of ferroptosis via regulating the FGFR3/PI3K/AKt signaling pathway |
MoA Biomarker | biomarkers offer a promising, non-invasive approach to personalizing treatment strategies potentially enhanci |
PK/PD Species | Rabbit, ration, inhibited xenograft |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit, ration, inhibited xenograft |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Bakuchiol Enhances 5-Fluorouracil Efficacy in Colorectal Cancer Cells via a ROS-Dependent Mechanism Involving Mitochondrial Dysfunction and Apoptosis.. Resistance to 5-fluorouracil (5-FU) remains a major limitation in colorectal cancer therapy, prompting the development of combination strategies aimed at improving its efficacy. Bakuchiol (BAK), a natural compound with reported antioxidant and pro-… |
Clinical Primary efficacy | ORR 72.6% |
Clinical ORR | 72.6% |
Clinical Result source | ClinicalTrials.gov NCT03615326 |
Clinical Data Tier / Score | A · 67 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교